Daniel Morgensztern - Concepedia

Author

Daniel Morgensztern

Washington University in St. Louis ORCID

Also Known As

D Morgensztern, D. Morgensztern, Daniel Morgenstzern, Daniel Morgensztern, Ikuo Fukuda

432

Publications

20K

Citations

H-Index

Concepts

All Affiliations

Washington University in St. Louis The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Duke Medical Center Massachusetts General Hospital

About

Daniel Morgensztern is an author at Washington University in St. Louis specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	59	5.5K
2	Health Sciences	15	16	2.4K
3	Engineering	1	1	13
4	Public Health	1	1	29
5	Biomedical Engineering	1	1	13

Daniel Morgensztern

106

Publications

11.7K

Citations

H-Index

Page 1

	Year	Citations
Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database Ramaswamy Govindan, Nathan Page, Daniel Morgensztern, Journal of Clinical Oncology	2006	1.8K
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Journal of the National Comprehensive Cancer Network Version 3.2022Advanced Lung DiseaseMedicineCancer ManagementMetastatic Nsclc	2022	1.4K
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Journal of the National Comprehensive Cancer Network	2021	990
Non–Small Cell Lung Cancer, Version 4.2024 Gregory J. Riely, Douglas E. Wood, David S. Ettinger, Journal of the National Comprehensive Cancer Network Tumor BiologyActionable Molecular BiomarkersAdvanced Lung DiseaseVersion 4.2024Medicine	2024	614
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, The Lancet Oncology Dll3-targeted Antibody-drug ConjugateMedicineImmunologyImmune Checkpoint InhibitorCancer Treatment	2016	537
Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, Shean Huey Ng, Feng Gao, Journal of Thoracic Oncology Stage DistributionMedicineCancer ManagementBronchial NeoplasmPulmonary Blastoma	2010	532
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023 David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Journal of the National Comprehensive Cancer Network	2023	449
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Clinical Cancer Research	2019	309
NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018 Gregory P. Kalemkerian, Billy W. Loo, Wallace Akerley, Journal of the National Comprehensive Cancer Network	2018	294
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 Taofeek K. Owonikoko, Keunchil Park, Ramaswamy Govindan, Journal of Clinical Oncology	2021	254

Page 1